Related Experiment Video

Updated: May 28, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

CBLB inhibits papillary thyroid cancer malignancy via negatively regulating MYCBP/c-Myc axis

Yanli Yang1, Xiaoyan Pei1, Qingqing Yang1

  • 1Department of Endocrinology, The First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.

Cellular Signalling
|May 26, 2026
PubMed

Insights

CBLB functions as a tumor suppressor in papillary thyroid carcinoma (PTC). It targets MYCBP for degradation, inhibiting the c-Myc pathway and suppressing PTC progression, indicating therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Papillary thyroid carcinoma (PTC) incidence is rising globally, but its molecular drivers are not fully understood.
  • Identifying novel tumor suppressors is crucial for understanding PTC pathogenesis.

Purpose of the Study:

  • To investigate the role of CBLB as a tumor suppressor in papillary thyroid carcinoma.
  • To elucidate the molecular mechanism by which CBLB regulates PTC progression.

Main Methods:

  • Analysis of public databases (GEPIA, UALCAN) and PTC cell lines to assess CBLB expression.
  • Functional experiments involving CBLB knockdown and overexpression to evaluate its impact on PTC phenotypes.
  • Mechanistic studies to determine CBLB's interaction with MYCBP and its effect on the c-Myc pathway.

Main Results:

  • CBLB expression is significantly reduced in PTC tissues compared to normal thyroid tissues.
  • CBLB knockdown enhances PTC malignant phenotypes, while CBLB overexpression suppresses them.
  • CBLB directly binds to MYCBP, promoting its ubiquitination and degradation, which subsequently inhibits the c-Myc pathway and affects oncogenic targets.

Conclusions:

  • The CBLB/MYCBP/c-Myc axis is a critical regulator of PTC progression.
  • CBLB acts as a tumor suppressor by targeting MYCBP and inhibiting oncogenesis.
  • CBLB presents therapeutic potential for targeting MYCBP-driven oncogenesis in PTC.
Keywords:
C-MycCBLBMYCBPPapillary thyroid cancerUbiquitination

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...